Department of Pancreatic surgery, Huashan Hospital, Fudan University, Shanghai, 200040, P. R. China.
Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, P. R. China.
Br J Cancer. 2020 Sep;123(6):1012-1023. doi: 10.1038/s41416-020-0929-0. Epub 2020 Jun 30.
The molecular signature underlying pancreatic ductal adenocarcinoma (PDAC) progression may include key proteins affecting the malignant phenotypes. Here, we aimed to identify the proteins implicated in PDAC with different tumour-node-metastasis (TNM) stages.
Eight-plex isobaric tags coupled with two-dimensional liquid chromatography-tandem mass spectrometry were used to analyse the proteome of PDAC tissues with different TNM stages. A loss-of-function study was performed to evaluate the oncogenic roles of WD repeat-containing protein 1 (WDR1) in PDAC. The molecular mechanism by which WDR1 promotes PDAC progression was studied by real-time qPCR, Western blotting, proximity ligation assay and co-immunoprecipitation.
A total of 5036 proteins were identified, and 4708 proteins were quantified with high confidence. Compared with normal pancreatic tissues, 37 proteins were changed significantly in PDAC tissues of different stages. Moreover, 64 proteins were upregulated or downregulated in a stepwise manner as the TNM stages of PDAC increased, and 10 proteins were related to tumorigenesis. The functionally uncharacterised protein, WDR1, was highly expressed in PDAC and predicted a poor prognosis. WDR1 knockdown suppressed PDAC tumour growth and metastasis in vitro and in vivo. Moreover, WDR1 knockdown repressed the activity of the Wnt/β-Catenin pathway; ectopic expression of a stabilised form of β-Catenin restored the suppressive effects of WDR1 knockdown. Mechanistically, WDR1 interacted with USP7 to prevent ubiquitination-mediated degradation of β-Catenin.
Our study identifies several previous functional unknown proteins implicated in the progression of PDAC, and provides new insight into the oncogenic roles of WDR1 in PDAC development.
胰腺导管腺癌(PDAC)进展的分子特征可能包括影响恶性表型的关键蛋白。在这里,我们旨在鉴定不同肿瘤-淋巴结-转移(TNM)分期的 PDAC 中涉及的蛋白。
使用 8 重同位素标记与二维液相色谱-串联质谱联用技术分析不同 TNM 分期的 PDAC 组织的蛋白质组。进行功能丧失研究以评估 WD 重复蛋白 1(WDR1)在 PDAC 中的致癌作用。通过实时 qPCR、Western blot、邻近连接测定和共免疫沉淀研究了 WDR1 促进 PDAC 进展的分子机制。
共鉴定了 5036 种蛋白质,其中 4708 种蛋白质具有高可信度。与正常胰腺组织相比,不同分期 PDAC 组织中有 37 种蛋白发生了显著变化。此外,随着 PDAC 的 TNM 分期逐渐升高,有 64 种蛋白呈逐步上调或下调趋势,其中 10 种蛋白与肿瘤发生有关。功能未明确的蛋白 WDR1 在 PDAC 中高表达,预示预后不良。WDR1 敲低抑制了 PDAC 肿瘤的体外和体内生长和转移。此外,WDR1 敲低抑制了 Wnt/β-Catenin 通路的活性;稳定形式的β-Catenin 的异位表达恢复了 WDR1 敲低的抑制作用。机制上,WDR1 与 USP7 相互作用,防止β-Catenin 的泛素化介导降解。
本研究鉴定了几个以前在 PDAC 进展中涉及的功能未知的蛋白,并为 WDR1 在 PDAC 发生发展中的致癌作用提供了新的见解。